Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma

Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma

Epidermal growth factor receptor (EGFR) is highly overexpressed in malignant mesothelioma (MM). MAb806 is a novel anti-EGFR antibody that selectively targets a tumor-selective epitope. MAb806-derived antibody drug conjugates (ADCs), ABT-414, ABBV-221 and ABBV-322, may represent a novel therapeutic s...

Full description

Bibliographic Details
Main Authors: Puey-Ling Chia, Sagun Parakh, Ming-Sound Tsao, Nhu-An Pham, Hui K. Gan, Diana Cao, Ingrid J. G. Burvenich, Angela Rigopoulos, Edward B. Reilly, Thomas John, Andrew M. Scott
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Pharmaceuticals
Subjects:
EGFR
malignant mesothelioma
806-ADC
<sup>89</sup>Zr-ch806
Online Access:https://www.mdpi.com/1424-8247/13/10/289

Internet

https://www.mdpi.com/1424-8247/13/10/289

Similar Items